Cogent Biosciences Touts Bezuclastinib Pivotal Wins, Eyes Up to Three FDA Filings and U.S. Launches [Yahoo! Finance]
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: Yahoo! Finance
systemic mastocytosis, plus GIST), and Cogent is preparing parallel NDA submissions with potential U.S. launches in one to all three indications depending on FDA review, targeting full commercialization by early 2027. Cogent estimates a U.S. moderate-to-severe non-advanced systemic mastocytosis population of ~6,000–8,000 and a Western markets TAM of about $3.5–$4 billion , arguing bezuclastinib's KIT selectivity and lack of CNS penetration deliver stronger symptom and biomarker responses and a better safety profile versus avapritinib. In GIST, the PEAK combination with sunitinib showed a median PFS of 16.5 months and an objective response rate near 50%, and Cogent says CMC is ready, expanded access programs are active, and it has begun building a commercial team (~40 hires) ahead of launch. Interested in Cogent Biosciences, Inc.? Here are five stocks we like better. Cogent Biosciences (NASDAQ:COGT) CEO Andrew Robbins outlined the company's transition into a pre-commercial stag
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- Cogent Biosciences (COGT) had its "outperform" rating reaffirmed by Wedbush. They now have a $55.00 price target on the stock.MarketBeat
- Cogent Biosciences (COGT) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.MarketBeat
- Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)GlobeNewswire
- Is Cogent Biosciences (COGT) One of the Best Multibagger Stocks to Buy According to Billionaires? [Yahoo! Finance]Yahoo! Finance
COGT
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form S-8
- 2/17/26 - Form SCHEDULE
- COGT's page on the SEC website